Human Biodistribution and Dosimetry of [C]-UCB-J, a PET Radiotracer for Imaging Synaptic Density

Overview

Journal EJNMMI Phys

Specialty Radiology

Date 2021 Apr 23

PMID 33891195

Citations 4

Authors

Christopher Cawthorne

Paul Maguire

Joel Mercier

David Sciberras

Kim Serdons

Guy Bormans

Jan de Hoon

Koen Van Laere

Michel Koole

Affiliations

Soon will be listed here.

Abstract

Rationale: [C]-UCB-J is an emerging tool for the noninvasive measurement of synaptic vesicle density in vivo. Here, we report human biodistribution and dosimetry estimates derived from sequential whole-body PET using two versions of the OLINDA dosimetry program.

Methods: Sequential whole-body PET scans were performed in 3 healthy subjects for 2 h after injection of 254 ± 77 MBq [C]-UCB-J. Volumes of interest were drawn over relevant source organs to generate time-activity curves and calculate time-integrated activity coefficients, with effective dose coefficients calculated using OLINDA 2.1 and compared to values derived from OLINDA 1.1 and those recently reported in the literature.

Results: [C]-UCB-J administration was safe and showed mixed renal and hepatobiliary clearance, with largest organ absorbed dose coefficients for the urinary bladder wall and small intestine (21.7 and 23.5 μGy/MBq, respectively). The average (±SD) effective dose coefficient was 5.4 ± 0.7 and 5.1 ± 0.8 μSv/MBq for OLINDA versions 1.1 and 2.1 respectively. Doses were lower than previously reported in the literature using either software version.

Conclusions: A single IV administration of 370 MBq [C]-UCB-J corresponds to an effective dose of less than 2.0 mSv, enabling multiple PET examinations to be carried out in the same subject.

Trial Registration: EudraCT number: 2016-001190-32. Registered 16 March 2016, no URL available for phase 1 trials.

Citing Articles

Human biodistribution and radiation dosimetry for the tau tracer [F]Florzolotau in healthy subjects.

Lin K, Huang S, Huang K, Huang C, Hsiao I EJNMMI Radiopharm Chem. 2024; 9(1):27.

PMID: 38563872 PMC: 10987466. DOI: 10.1186/s41181-024-00259-x.

Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives.

Lista S, Santos-Lozano A, Emanuele E, Mercuri N, Gabelle A, Lopez-Ortiz S Mol Psychiatry. 2024; 29(3):847-857.

PMID: 38228892 DOI: 10.1038/s41380-023-02376-6.

Imaging of Brain Structural and Functional Effects in People With Human Immunodeficiency Virus.

OConnor E, Sullivan E, Chang L, Hammoud D, Wilson T, Ragin A J Infect Dis. 2023; 227(Suppl 1):S16-S29.

PMID: 36930637 PMC: 10022717. DOI: 10.1093/infdis/jiac387.

Detecting Early Cognitive Decline in Alzheimer's Disease with Brain Synaptic Structural and Functional Evaluation.

Ribaric S Biomedicines. 2023; 11(2).

PMID: 36830892 PMC: 9952956. DOI: 10.3390/biomedicines11020355.

References

Finnema S, Rossano S, Naganawa M, Henry S, Gao H, Pracitto R . A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia. 2019; 60(5):958-967. PMC: 6532410. DOI: 10.1111/epi.14701. View

Zanotti-Fregonara P, Innis R . Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2011; 39(3):544-7. PMC: 3791506. DOI: 10.1007/s00259-011-2005-8. View

Koole M, van Aalst J, Devrome M, Mertens N, Serdons K, Lacroix B . Quantifying SV2A density and drug occupancy in the human brain using [C]UCB-J PET imaging and subcortical white matter as reference tissue. Eur J Nucl Med Mol Imaging. 2018; 46(2):396-406. DOI: 10.1007/s00259-018-4119-8. View

. Human alimentary tract model for radiological protection. ICRP Publication 100. A report of The International Commission on Radiological Protection. Ann ICRP. 2006; 36(1-2):25-327, iii. DOI: 10.1016/j.icrp.2006.03.004. View

Holmes S, Scheinost D, Finnema S, Naganawa M, Davis M, DellaGioia N . Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019; 10(1):1529. PMC: 6449365. DOI: 10.1038/s41467-019-09562-7. View

Petrulli J, Hansen S, Abourbeh G, Yaqub M, Bahce I, Holden D . A multi species evaluation of the radiation dosimetry of [C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. Nucl Med Biol. 2017; 47:56-61. PMC: 5360653. DOI: 10.1016/j.nucmedbio.2016.12.009. View

Cai Z, Li S, Matuskey D, Nabulsi N, Huang Y . PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. Neurosci Lett. 2018; 691:44-50. PMC: 6339829. DOI: 10.1016/j.neulet.2018.07.038. View

Mertens N, Maguire R, Serdons K, Lacroix B, Mercier J, Sciberras D . Validation of Parametric Methods for [C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue. Mol Imaging Biol. 2019; 22(2):444-452. DOI: 10.1007/s11307-019-01387-6. View

Gnesin S, Cicone F, Mitsakis P, Van Der Gucht A, Baechler S, Miralbell R . First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist Ga-NODAGA-MJ9. EJNMMI Res. 2018; 8(1):108. PMC: 6291411. DOI: 10.1186/s13550-018-0462-9. View

10.

Chen M, Mecca A, Naganawa M, Finnema S, Toyonaga T, Lin S . Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurol. 2018; 75(10):1215-1224. PMC: 6233853. DOI: 10.1001/jamaneurol.2018.1836. View

11.

Stabin M, Siegel J, Xu X . RADAR Develops New Generation of Dosimetry Phantoms. J Nucl Med. 2018; 59(5):11N. View

12.

Melendez-Alafort L, Ferro-Flores G, De Nardo L, Bello M, Paiusco M, Negri A . Internal radiation dose assessment of radiopharmaceuticals prepared with cyclotron-produced Tc. Med Phys. 2019; 46(3):1437-1446. DOI: 10.1002/mp.13393. View

13.

Mansur A, Rabiner E, Comley R, Lewis Y, Middleton L, Huiban M . Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain: F-BCPP-EF, C-SA-4503, and C-UCB-J. J Nucl Med. 2019; 61(1):96-103. DOI: 10.2967/jnumed.119.228080. View

14.

. ICRP Publication 30, Part 1, 1979. Ann ICRP. 2010; 2(3-4P1):i-iv. DOI: 10.1016/0146-6453(79)90096-4. View

15.

Nicastro N, Holland N, Savulich G, Carter S, Mak E, Hong Y . C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies. Eur J Hybrid Imaging. 2020; 4(1):25. PMC: 7752786. DOI: 10.1186/s41824-020-00093-9. View

16.

Finnema S, Nabulsi N, Mercier J, Lin S, Chen M, Matuskey D . Kinetic evaluation and test-retest reproducibility of [C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. J Cereb Blood Flow Metab. 2017; 38(11):2041-2052. PMC: 6259313. DOI: 10.1177/0271678X17724947. View

17.

Bini J, Holden D, Fontaine K, Mulnix T, Lu Y, Matuskey D . Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand C-UCB-J. EJNMMI Res. 2020; 10(1):83. PMC: 7359974. DOI: 10.1186/s13550-020-00670-w. View

18.

Smart K, Liu H, Matuskey D, Chen M, Torres K, Nabulsi N . Binding of the synaptic vesicle radiotracer [C]UCB-J is unchanged during functional brain activation using a visual stimulation task. J Cereb Blood Flow Metab. 2020; 41(5):1067-1079. PMC: 8054713. DOI: 10.1177/0271678X20946198. View

19.

Mercier J, Provins L, Valade A . Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications. Drug Discov Today Technol. 2017; 25:45-52. DOI: 10.1016/j.ddtec.2017.11.003. View

20.

Nabulsi N, Mercier J, Holden D, Carre S, Najafzadeh S, Vandergeten M . Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. J Nucl Med. 2016; 57(5):777-84. DOI: 10.2967/jnumed.115.168179. View